BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
6:55 AM | Monday | Oct 12, 2026 Business Wire

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

News Thumbnail
6:50 AM | Monday | Oct 12, 2026 Business Wire

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

News Thumbnail
6:59 AM | Thursday | Oct 8, 2026 Business Wire

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.

News Thumbnail
6:59 AM | Thursday | Oct 1, 2026 Business Wire

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

News Thumbnail
10:00 AM | Friday | Sep 25, 2026 Business Wire

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUSâ„¢ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

News Thumbnail
6:59 AM | Friday | Sep 18, 2026 Business Wire

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

News Thumbnail
6:59 AM | Thursday | Sep 17, 2026 Business Wire

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

News Thumbnail
6:59 AM | Wednesday | Sep 16, 2026 Business Wire

Bristol Myers Squibb Announces Dividend

News Thumbnail
6:59 AM | Tuesday | Sep 8, 2026 Business Wire

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel

News Thumbnail
11:00 AM | Saturday | Aug 29, 2026 Business Wire

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

News Thumbnail

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

Business Wire

6:55 AM | Monday | Oct 12, 2026

news photo
Loading...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101.

Read full article redirect
6:55 AM | Monday | Oct 12, 2026

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101.

Read full article arrow
News Thumbnail
6:50 AM | Monday | Oct 12, 2026

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint.

Read full article arrow
News Thumbnail
6:59 AM | Thursday | Oct 8, 2026

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior.

Read full article arrow
News Thumbnail
6:59 AM | Thursday | Oct 1, 2026

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement.

Read full article arrow
News Thumbnail
10:00 AM | Friday | Sep 25, 2026

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUSâ„¢ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUSâ„¢ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial.

Read full article arrow
News Thumbnail
6:59 AM | Friday | Sep 18, 2026

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026.

Read full article arrow
News Thumbnail
6:59 AM | Thursday | Sep 17, 2026

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CCRWest2026--Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years.

Read full article arrow
News Thumbnail
6:59 AM | Wednesday | Sep 16, 2026

Bristol Myers Squibb Announces Dividend

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

Read full article arrow
News Thumbnail
6:59 AM | Tuesday | Sep 8, 2026

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial.

Read full article arrow
News Thumbnail
11:00 AM | Saturday | Aug 29, 2026

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).

Read full article arrow
News Thumbnail